Skip to Content

CAR T-Cell Therapy: A Healthcare Professional's Guide - An Overview

Medically reviewed by L. Anderson, PharmD Last updated on Oct 1, 2018.

CAR T-Cell Therapy: An Introduction

Chimeric antigen receptor (CAR) T-cell therapy is an investigational form of immunotherapy -- in fact, the first gene therapy -- now FDA-approved. CAR T cell therapy is offering promising options for patients and clinicians who are struggling with refractory cancers that do not respond to, or are ineligible for other standard options, such as surgery, radiation, chemotherapy, or bone marrow transplant.

There are 3 main types of lymphocytes (white blood cells) that have action against cancerous tumors:

  • B cells
  • T cells
  • Natural killer (NK) cells

CAR T-cell therapy works with the patient's own immune system to help boost the cancer-killing effects of the T lymphocyte. Normally, T-cells have a direct killing action on cancer cells and also communicate with the immune system via cytokines -- cell signalling molecules. However, cancer cells can evade the T lymphocytes. The T-cells become less effective, have low proliferation, and don't recognize cancer as a foreign body.

CAR T-Cells: Getting Aggressive on Cancer

Simply put, CAR T-cell therapy is a biomedical engineering feat.

The patient's own T-cells are modified to recognize tumor antigens and attack the cancer cells. What kinds of cancers are CAR T agents treating?

Aggressive B-cell non-Hodgkin lymphoma is a malignancy with a new CAR T-cell approval. On October 18, 2017, Kite Pharma/Gilead's axicabtagene ciloleucel (Yescarta) was approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Data from Kite's ZUMA-1 trial supported the new drug application (NDA).

Leukemias, such as acute lymphoblastic leukemia (ALL), have also shown extended remissions in studies with CAR T-cell therapy. Yong and colleagues also report on evolving research involving CAR T-cells directed against solid tumors like:

  • Glioblastomas (brain tumors)
  • Liver cancer
  • Breast cancer
  • Lung cancer
  • Pancreatic cancer

CAR T-Cell Therapy: A Living Drug

CAR T-cell therapy involves several steps:

  1. First, blood is taken from the patient via leukapheresis to collect the lymphocytes. The T cells are then isolated.
  2. Next, the T cells are genetically engineered in the laboratory to produce chimeric antigen receptors (CARs) -- a protein -- on their surface. The genes are inserted into the T cells using an inactive virus. This process leads to the CAR T-cell that recognizes the cancer antigen on the targeted tumor cell.
  3. The engineered CAR T-cell is then grown in the laboratory for about 2 weeks to produce billions of more cells. The cells are frozen and sent to the hospital where the patient will undergo treatment. The patient receives chemotherapy to kill off some of their white cells prior to infusion. This helps the body to better accept the CAR T-cells.
  4. The CAR T-cells are re-infused into the patient where they continue to multiply, seek out, and attack the tumor target antigen. CAR T-cells remain in the body after infusion and can continue to function. In investigational studies, some patients have been able to maintain long-term remissions possibly due to this effect.

CAR T-Cell Therapy: The Structure

What are CAR T-cells? CARs are fusion proteins that contain 3 distinct functional domains:

  • The first domain is an antibody fragment, also called a target-binding domain, that elicits signals to activate the engineered T cells to recognize and bind to target antigens on the surface of the cancer cell.
  • The second component, called the costimulatory domain, allows the CAR T-cells to proliferate and survive.
  • The third domain, called the essential activation domain, activates the CAR T-cells.

Many different antigen targets are under research; however, the most common antigen that has been targeted in lymphoma and leukemia trials is known as "cluster of differentiation 19" (CD19). CD19 is expressed on the surface of most B cells, both healthy and cancerous. CD19 is not found on other healthy cells, and therefore those cells are not targeted by the engineered CAR T-cell.

B-cell aplasia is reported as an expected side effect, and can boost the risk of infections, but has been managed with intravenous immunoglobulin replacement.

For a detailed description of the mechanism, view this video from Kite Pharma: Chimeric Antigen Receptor (CAR)

CAR T: Further Questions and Ongoing Research

Scientists and clinicians alike are excited about this new therapy that may offer extended survival to certain patients who have exhausted their options for cancer treatments.

Results have been especially promising in patients with cancers such as aggressive non-Hodgkin lymphomas like diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), primary mediastinal B-cell lymphoma (PMBCL), certain leukemias such as ALL and CLL, and multiple myelomas.

However, there are many questions:

  1. How long is CAR T-cell therapy effective? While some studies have reported extended periods of remission, patients will need to be followed long-term to answer this question.
  2. What is the cost of CAR T-cell therapy? Genetically engineering personalized immunotherapy is expensive and complicated. The price tag of the first approval, Kymriah (tisagenlecleucel) from Novartis is set at $475,000 per treatment. Yescarta (axicabtagene ciloleucel) from Gilead/Kite Pharma is expected to run about $373,000 per treatment regimen. Will the healthcare system be able to bear the burden of this cost? What portion will patients be responsible for?
  3. Can CAR T-cells from donors be harvested and stored, or can a "universal" CAR-T agent be successfully developed? Researchers from the National Cancer Institute (NCI) have reported promising results from a trial using donor-derived CAR T-cells in lymphoma and leukemia.
  4. Can immune checkpoint inhibitors and CAR-T therapy be successfully combined for synergistic effect and to lower doses and side effects?

Targeted Therapy: Advances Continue

While there are still questions to be answered, CAR T-cell therapy has made tremendous advancements in the last two decades.

The first clinical trial with CAR T-cells was in 1996 targeting ovarian cancer, but success was limited in early studies. However, dedicated researchers have now brought forth significant advances into personalized, targeted immunotherapies:

  • Therapeutic cancer vaccines such as sipuleucel-T (Provenge) for men with metastatic prostate cancer
  • Immune checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo) used for non-small cell lung cancer (NSCLC), melanoma, and many other malignancies
  • CAR T-cell therapy such as the FDA-approved Yescarta (axicabtagene ciloleucel) given the go-ahead by the FDA in October 2017 for treatment of adult patients with large B-cell lymphoma after at least two other kinds of treatment failed, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Kymriah (tisagenlecleucel) was approved in August 2017 for use in relapsed and refractory (r/r) patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL). In May 2018, Kymriah was also approved for relapsed or refractory large b-cell lymphoma in adults after two or more therapies.
  • Investigational T cell receptor (TCR) engineered T cells in research for solid tumors.

Finished: CAR T-Cell Therapy: A Healthcare Professional's Guide - An Overview

CAR T-Cell Therapy: A Healthcare Professional's Guide: Introduction - The Tumor

Immunotherapy is becoming a standard method of cancer treatment. Learn the basics of the cancerous tumor type, how cancers evade the immune system, and which novel immunotherapy treatments - like…


Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.